Research map: Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study

Back to the article

Papers in this map

  1. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia · Hagop M. Kantarjian · 2016 · 1415 citations · Cited by this paper
  2. Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients · 2026 · Related
  3. Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia · Hagop M. Kantarjian · 2000 · 798 citations · Cited by this paper
  4. Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma · 2026 · Related
  5. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) · Anthony H. Goldstone · 2007 · 786 citations · Cited by this paper
  6. Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study · 2026 · Related
  7. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome–positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol · Marco Vignetti · 2007 · 375 citations · Cited by this paper
  8. Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial · 2026 · Related
  9. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study · Hagop M. Kantarjian · 2018 · 240 citations · Cited by this paper
  10. Preclinical and clinical efficacy of the HDAC6 inhibitor ricolinostat in combination with BCR pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia · 2026 · Related
  11. Minimal residual disease is a significant predictor of treatment failure in non T‐lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993 · Bella Patel · 2009 · 154 citations · Cited by this paper
  12. Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine · 2026 · Related
  13. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial · Elias Joseph Jabbour · 2023 · 118 citations · Cited by this paper
  14. Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma · 2026 · Related
  15. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome–Negative B-Precursor ALL · Matthias Stelljes · 2023 · 88 citations · Cited by this paper
  16. Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin · 2026 · Related
  17. Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 + Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia · Patrice Chevallier · 2024 · 46 citations · Cited by this paper
  18. Arterial thrombosis and cancer: insights from observations in myeloproliferative neoplasms and CHIP · 2026 · Related
  19. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia is a strong predictor for survival · Musa E. Yilmaz · 2019 · 40 citations · Cited by this paper
  20. The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma · 2026 · Related
  21. Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results · Matthew Joseph Wieduwilt · 2025 · 11 citations · Cited by this paper
  22. Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL · Nicholas James Short · 2025 · 10 citations · Cited by this paper

Source: OpenAlex (CC0)